Your email has been successfully added to our mailing list.

×
1.5419764230905E-16 1.5419764230905E-16 1.5419764230905E-16 -0.0383333333333333 -0.0555555555555555 -0.0827777777777776 -0.00938888888888872 -0.0438888888888888
Stock impact report

Mateon Therapeutics Appoints Dr. Anthony Maida as Chief Clinical Officer - Translational Medicine

MATEON THERAPEUTICS (MATN) 
Last mateon therapeutics earnings: 11/19 05:25 pm Check Earnings Report
US:NASDAQ Investor Relations: investor.mateon.com
Company Research Source: GlobeNewswire
Company expands its management team to accelerate the evaluation of OT-101 for Oncology and COVID-19 Agoura Hills, California, July 07, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics (OTC.QB: MATN), a late-stage biotechnology company developing Trabedersen (OT-101), a TGF-ß inhibitor with the potential for multiple therapeutic indications including glioblastoma, pancreatic cancer, melanoma and COVID-19, appointed Anthony Maida, III, Ph.D., MA, MBA as Chief Clinical Officer - Translational Medicine for the Company. Dr. Maida, a director of the Company since 2015, will retain his position as Board of Director. Dr. Maida is an expert in the clinical development of immuno-oncology and related products. For close to 30 years, Dr. Maida has been involved in all aspects of commercial clinical, preclinical and scientific development of biotherapeutics including translational medicine, protocol design, FDA interactions, manufacturing process validation, and data assessment. He has served Show less Read more
Impact Snapshot
Event Time:
MATN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for MATN alerts
Opt-in for
MATN alerts

from News Quantified
Opt-in for
MATN alerts

from News Quantified